Shopping Cart
- Remove All
- Your shopping cart is currently empty
CG0009 is a potent and highly selective glycogen synthase kinase 3 (GSK3) inhibitor that inhibitions proliferation, induces apoptosis, and activates the p53-Bax pathway in breast cancer cells through cyclin D1 depletion. CG0009 inhibit breast cancer cell growth through cyclin D1 depletion and p53 activation, and thus may provide an innovative treatment approach for breast cancer resistant to hormone-based therapies.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
25 mg | 1.586 € | 6-8 weeks | |
50 mg | 2.071 € | 6-8 weeks | |
100 mg | 2.660 € | 6-8 weeks |
Description | CG0009 is a potent and highly selective glycogen synthase kinase 3 (GSK3) inhibitor that inhibitions proliferation, induces apoptosis, and activates the p53-Bax pathway in breast cancer cells through cyclin D1 depletion. CG0009 inhibit breast cancer cell |
Alias | CG-0009, CG 0009 |
Molecular Weight | 457.57 |
Formula | C26H31N7O |
Cas No. | 944744-57-4 |
Relative Density. | no data available |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.